RZLT
Rezolute, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.58
+0.88%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -7.2%
- EBIT
- -13.1%
- EPS
- +29.3%
- Free cash flow
- -12.0%
- Operating cash flow
- -12.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +27.6%
- EPS
- +30.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -8.7%
- EBIT
- -13.4%
- Net income
- -8.7%
- EPS
- +26.3%
- Free cash flow
- -20.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026